Business

As Stellantis trudges through tumultuous waters, the third-quarter sales figures reveal critical challenges facing the automaker. Reporting sales of 305,294 vehicles between July and September, Stellantis experienced a staggering decline of 19.8% compared to the same quarter in 2022, with an even sharper drop of 11.5% against the previous quarter of 2023. The outlook appeared
0 Comments
Dish Network’s journey resembles that of its namesake sitcom “Seinfeld”—filled with promise yet concluding in disappointment. Co-founder Charlie Ergen, during a 2011 earnings call, drew parallels between the cable giant’s strategic direction and the narrative style of the 1990s comedy. Ergen famously shared how “Seinfeld” episodes began with divergent storylines, only to unite in an
0 Comments
In recent years, the National Basketball Association (NBA) has witnessed a remarkable increase in team valuations, prompting various investors to reassess their portfolios and dive deeper into the basketball business. Notably, businessman Paul Viera is capitalizing on this trend by enhancing his stake in the San Antonio Spurs from 5% to 11%. Such moves not
0 Comments
The ongoing debate surrounding prescription drug prices in the United States reached a critical juncture as Novo Nordisk’s CEO Lars Fruergaard Jørgensen faced a Senate inquiry regarding the alarming costs of the company’s weight loss drug Wegovy and diabetes medication Ozempic. The hearing, held by the Senate Health, Education, Labor and Pensions Committee, aimed to
0 Comments
In a recent internal communication, Southwest Airlines has alerted its workforce to the challenging decisions that lie ahead as it strives to enhance profitability amidst growing pressure from activist investor Elliott Investment Management. This investment firm has reportedly pushed for a leadership overhaul within the airline, citing concerns about the current management’s efficacy in improving
0 Comments
On a pivotal Friday, the Federal Trade Commission (FTC) filed a major lawsuit against three sizable U.S. health companies that act as intermediaries in the insulin pricing system. These companies, known as pharmacy benefit managers (PBMs), are accused of employing strategies that inflate insulin costs for patients while simultaneously padding their profit margins. The targets
0 Comments